OX40/OX40L in systemic lupus erythematosus: association with disease activity and lupus nephritis
- PMID: 21245596
- PMCID: PMC3101721
- DOI: 10.4103/0256-4947.75775
OX40/OX40L in systemic lupus erythematosus: association with disease activity and lupus nephritis
Abstract
Background and objectives: OX40-OX40L interaction is implicated in the pathogenesis of systemic lupus erythematosus (SLE). We evaluated the role of OX40/OX40L as markers of disease activity and nephritis in SLE patients.
Design and setting: Case-control study conducted in 2009 on SLE patients attending the outpatient clinics of Ain Shams University Hospital, Egypt.
Patients and methods: We assessed the percentage of CD4+ T-lymphocytes expressing OX40 by flowcytometry, and serum OX40 ligand (OX40L) levels in 40 patients with SLE (20 with lupus nephritis and 20 without) and in 20 healthy controls. Disease activity was assessed by the University of Toronto SLE disease activity index (SLEDAI).
Results: The percentage of CD4+ T-lymphocytes expressing OX40 was significantly higher in SLE patients than in controls, and in patients with lupus nephritis than in those without. OX40 expression correlated positively with both serum creatinine levels and SLEDAI. OX40 expression was the highest in patients with class V lupus nephritis and lowest in class II. Serum OX40L levels were significantly higher in SLE patients than in controls, and in patients with nephritis than in those without. Serum OX40L levels correlated with serum creatinine levels but not with SLEDAI. OX40 expression on CD4+ T-cells had a higher sensitivity and specificity in diagnosing lupus nephritis than both OX40L and anti-double-stranded DNA levels.
Conclusion: OX40-OX40L interaction plays a role in the pathogenesis of SLE. The expression of OX40 on CD4+ T-lymphocytes and the serum level of OX40L may act as markers of lupus nephritis. Measurements of percentages of CD4+ T-lymphocytes expressing OX40 may serve as an indicator of disease activity in SLE.
Figures




Similar articles
-
CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus.Clin Exp Immunol. 2006 Aug;145(2):235-42. doi: 10.1111/j.1365-2249.2006.03141.x. Clin Exp Immunol. 2006. PMID: 16879242 Free PMC article.
-
Blockade of OX40/OX40L signaling using anti-OX40L alleviates murine lupus nephritis.Eur J Immunol. 2024 Aug;54(8):e2350915. doi: 10.1002/eji.202350915. Epub 2024 May 27. Eur J Immunol. 2024. PMID: 38798163
-
The Ox40/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice.J Immunol. 2017 Aug 15;199(4):1238-1249. doi: 10.4049/jimmunol.1700608. Epub 2017 Jul 10. J Immunol. 2017. PMID: 28696253 Free PMC article.
-
Association of the co-stimulator OX40L with systemic lupus erythematosus.J Mol Med (Berl). 2009 Mar;87(3):229-34. doi: 10.1007/s00109-008-0431-2. Epub 2008 Dec 16. J Mol Med (Berl). 2009. PMID: 19083191 Review.
-
Interferon-Inducible Protein 10 and Disease Activity in Systemic Lupus Erythematosus and Lupus Nephritis: A Systematic Review and Meta-Analysis.Int J Mol Sci. 2019 Oct 8;20(19):4954. doi: 10.3390/ijms20194954. Int J Mol Sci. 2019. PMID: 31597273 Free PMC article.
Cited by
-
Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis.J Immunol Res. 2022 Feb 28;2022:4337399. doi: 10.1155/2022/4337399. eCollection 2022. J Immunol Res. 2022. PMID: 35265719 Free PMC article.
-
Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity.Acta Pharm Sin B. 2020 Mar;10(3):414-433. doi: 10.1016/j.apsb.2019.08.010. Epub 2019 Sep 3. Acta Pharm Sin B. 2020. PMID: 32140389 Free PMC article. Review.
-
Meta-analysis of genome-wide association study identifies FBN2 as a novel locus associated with systemic lupus erythematosus in Thai population.Arthritis Res Ther. 2020 Aug 8;22(1):185. doi: 10.1186/s13075-020-02276-y. Arthritis Res Ther. 2020. PMID: 32771030 Free PMC article.
-
Genetics of human lupus nephritis.Clin Immunol. 2017 Dec;185:32-39. doi: 10.1016/j.clim.2016.09.012. Epub 2016 Sep 28. Clin Immunol. 2017. PMID: 27693588 Free PMC article. Review.
-
The Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus.Cells. 2019 Oct 8;8(10):1213. doi: 10.3390/cells8101213. Cells. 2019. PMID: 31597242 Free PMC article. Review.
References
-
- Weinberg AD. OX40: Targeted immunotherapy--implications for tempering autoimmunity and enhancing vaccines. Trends Immunol. 2002;23:102–9. - PubMed
-
- Weinberg AD, Evans DE, Thalhofer C, Shi T, Prell RA. The generation of T cell memory: A review describing the molecular and cellular events following OX40 (CD134) engagement. J Leukoc Biol. 2004;75:962–72. - PubMed
-
- Manku H, Graham DS, Vyse TJ. Association of the co-stimulator OX40L with systemic lupus erythematosus. J Mol Med. 2009;87:229–34. - PubMed
-
- Tucci M, Calvani N, Richards HB, Quatraro C, Silvestris F. The interplay of chemokines and dendritic cells in the pathogenesis of lupus nephritis. Ann N Y Acad Sci. 2005;1051:421–32. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials